Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Erythrocyte Complement Receptor 1 and Alzheimer Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
CHU de Reims
ClinicalTrials.gov Identifier:
NCT01565434
First received: March 26, 2012
Last updated: June 8, 2016
Last verified: March 2012
  Purpose
Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.

Condition Intervention
Alzheimer Disease
Other: CR1 impact

Study Type: Interventional
Study Design: Primary Purpose: Screening

Resource links provided by NLM:


Further study details as provided by CHU de Reims:

Enrollment: 200
Study Start Date: February 2012
Study Completion Date: April 2015
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects

Exclusion Criteria:

  • diseases modifying CR1 physiology
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01565434

Locations
France
CHU de REIMS
Reims, France, 51092
Sponsors and Collaborators
CHU de Reims
  More Information

Responsible Party: CHU de Reims
ClinicalTrials.gov Identifier: NCT01565434     History of Changes
Other Study ID Numbers: PA11014 
Study First Received: March 26, 2012
Last Updated: June 8, 2016
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 27, 2016